Brian Wohlberg

Representative Experience

• The following companies in business combinations with a special purpose acquisition company (SPAC):
  • A cloud manufacturing and digital supply chain company in its business combination with a NASDAQ-listed SPAC valuing the combined enterprise at $1.4 billion.
  • A leading FinTech company in its $800 million business combination with an NYSE-listed SPAC.
  • A technology-enabled provider of value-based healthcare in its business combination with a NASDAQ-listed SPAC valuing the combined enterprise at $800 million.
• Deere & Company’s acquisition of Kreisel Electric, a leading developer of immersion-cooled battery technology.
• Deere & Company’s joint venture with GUSS Automation, a manufacturer of semi-autonomous orchard and vineyard sprayers.
• SolarWinds Corporation in its $1.9 billion spinoff of N-able, Inc.
• Appvion Operations in the sale of substantially all its assets to a private equity firm, as well as various divestiture transactions.
• Alliant Capital, an alternative investment manager, in its sale to Walker & Dunlop, Inc.
• The Arcticom Group, a service provider for commercial refrigeration and HVAC systems, in its sale to a private equity firm.
• AvaSure, a leading telehealth provider, in a significant equity financing from a private equity consortium.
• A private equity fund in a significant minority investment in a dark fiber and bandwidth provider.
• Obix, a leader in perinatal systems, in its sale to Harris, an operating group of Constellation Software Inc.
• NightOwl Global in its sale to HaystackID.
  
   

Prior to joining DLA Piper, Brian worked on the following representative matters:

• Hillenbrand, Inc. in its $2 billion acquisition of Milacron Holdings Corp.
• Essendant, Inc. in the termination of its merger agreement with Genuine Parts Company and subsequent $1 billion sale to an affiliate of Staples, Inc. 
• Ball Corporation in its: 
  • $675 million joint venture with Platinum Equity involving its U.S. food and aerosol packaging business.
  • $6.1 billion acquisition of Rexam plc and $3.1 billion simultaneous antitrust-related disposition of certain of its and Rexam’s businesses to Ardagh Group S.A.
• Cardinal Health, Inc. in its $6.1 billion acquisition of the patient care product portfolio of Medtronic plc.